Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BST-236 (Aspacytarabine) in R/R AML or Higher-Risk MDS
NCT04749355Phase 2Unknown
- Sponsor
- BioSight
- Start
- Nov 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of aspacytarabine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by BioSight. Status: unknown.
02
Drugs
aspacytarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04749355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04749355.